Research/P-02
P-02Metabolic47 studies indexed

Retatrutide

The next generation of fat loss.

By HelixHouse Research TeamPublished Last reviewed
01 · Overview

Retatrutide (LY3437943) is an investigational once-weekly injectable developed by Eli Lilly. It's a first-in-class triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously — which is why early Phase 2 results are showing weight loss substantially beyond what semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro) have produced.

02 · Mechanism of Action

Simultaneous agonism of three receptors: GLP-1 (appetite suppression, delayed gastric emptying, insulin sensitivity), GIP (improved lipid handling and insulin response), and glucagon (increased energy expenditure and hepatic fat oxidation). Most fat-loss drugs only hit one or two of these — retatrutide's third mechanism actively burns fat in addition to reducing intake.

03 · Current Evidence
  • E.01Phase 2 trial (NEJM 2023): 48-week mean weight loss of ~24% at the highest 12 mg dose — the largest reported in any published GLP-class trial.
  • E.02Significant reductions in HbA1c, blood pressure, and triglycerides observed across dose groups.
  • E.03Phase 3 TRIUMPH program currently enrolling for obesity, type 2 diabetes, and MASH (fatty liver disease).
04 · Reported Benefits
B.01Dramatic appetite suppression — food noise reportedly disappears
B.02Increased basal metabolic rate from glucagon activity
B.03Improved insulin sensitivity and glycemic control
B.04Reductions in liver fat and cardiovascular risk markers
05 · Safety Considerations

Not yet FDA-approved. Reported adverse events mirror the GLP-1 class: nausea, vomiting, diarrhea — mostly mild-to-moderate, dose-dependent, and reduced with careful titration. Long-term safety data pending Phase 3 completion.

06 · Common Stacks

Standalone therapy. Do not combine with other GLP-1 agonists (semaglutide, tirzepatide) — no clinical basis for stacking and risk profile stacks unfavorably.

07 · Regulatory Status

Investigational. Phase 3 trials ongoing. Not FDA-approved.

08 · References & Further Reading
R.01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial
New England Journal of Medicine (2023)
↗
R.02
Efficacy and safety of retatrutide in adults with type 2 diabetes
The Lancet (2023)
↗
R.03
TRIUMPH Phase 3 clinical trial program
ClinicalTrials.gov
↗
09 · Frequently Asked Questions
How does Retatrutide work?+
Simultaneous agonism of three receptors: GLP-1 (appetite suppression, delayed gastric emptying, insulin sensitivity), GIP (improved lipid handling and insulin response), and glucagon (increased energy expenditure and hepatic fat oxidation). Most fat-loss drugs only hit one or two of these — retatrutide's third mechanism actively burns fat in addition to reducing intake.
What are the reported benefits of Retatrutide?+
Dramatic appetite suppression — food noise reportedly disappears Increased basal metabolic rate from glucagon activity Improved insulin sensitivity and glycemic control Reductions in liver fat and cardiovascular risk markers Note: reported benefits vary and much of the evidence is preclinical.
Is Retatrutide safe?+
Not yet FDA-approved. Reported adverse events mirror the GLP-1 class: nausea, vomiting, diarrhea — mostly mild-to-moderate, dose-dependent, and reduced with careful titration. Long-term safety data pending Phase 3 completion.
What is the regulatory status of Retatrutide?+
Investigational. Phase 3 trials ongoing. Not FDA-approved.
Educational content only · Reviewed July 8, 2026 by HelixHouse Research Team

This page summarizes publicly available research. Nothing here is medical advice, a prescription, or a diagnosis. Peptides described are not FDA-approved for the uses discussed unless explicitly noted. Consult a qualified physician before starting any protocol.